2017
  |     |     |     |     |     |     |     |     |     |     |     |  

CVieTherapeutics Enrolled the First Patient in Phase 2b Clinical Study of Istaroxime in China 2016.12.02

Submitted New Drug Application to China FDA and Hong Kong DHon Zingo® for Needle-free Local Analgesia 2016.11.14

Kato Pharmaceuticals, Inc. and Lee’s Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize Resolvine ER in Greater China and South East Asia. 2016.10.07

Dilafor raises SEK 51 million to facilitate Phase IIb clinical study with Tafoxiparin 2016.09.27

Completed The First Subject in Clinical Study for Continuous Glucose Monitoring System in Hong Kong 2016.09.09

Beijing Shenogen Pharma Group Limited and Lee’s Pharmaceutical (HK) Limited Announce Development and Commercialization Collaboration Agreement for Pexa-Vec and Icaritin in China 2016.08.25

China FDA Grants Pharmaceutical Manufacturing License to Nansha Manufacturing Facility 2016.07.04

Lee's Pharm Announces its Chief Executive Officer, Dr. Benjamin Xiao-Yi Li awarded Honorary Fellowship from The Hong Kong University of Science and Technology 2016.06.16

RegeneRx and Lee’s Pharm Announce Acceleration of RGN-259 Development in China 2016.06.02

APPOINTMENT OF DR. LIT-FUI LAU AS PRESIDENT AND CHIEF OPERATING OFFICER OF CVIE THERAPEUTICS LIMITED 2016.05.16

U.S. FDA Grants Orphan Drug Designation to Anfibatide for Treatment of Thrombotic Thrombocytopenic Purpura 2016.03.24

Successful FDA Inspection with No 483 Issued to Powder Pharmaceuticals 2016.03.14

Salvat and Lee’s Pharmaceutical (HK) Limited Announce Exclusive License and Supply Agreement for Duoxal® in Greater China 2016.01.04

CVie Therapeutics enrolled the 1st patient for Phase 2b Clinical Trial of Rostafuroxin in Taiwan 2015.12.22

Lee’s Pharm Announces its Chief Executive Officer, Dr. Benjamin Li wins the EY Entrepreneur Of The Year® 2015 China Award 2015.12.08

Lee’s Pharm was honored at 2015’s Forbes Asia “Best Under A Billion” Award Ceremony 2015.12.08

Solasia and Lee’s Pharma Announce License, Promotion and Supply Agreement (the “Agreement”) for Sancuso® 2015.11.25

Tragara and Lee's Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize TG02in Greater China Market and South East Asia 2015.11.17

First Patient enrolled in Phase IIb Clinical Trial of Anfibatide in China 2015.10.28

Armetheon and Lee’s Pharma Enter into Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand 2015.09.22

Recently Published Study Shows Positive Results for ZiNGO® in Pediatric Patients 2015.09.11

WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee’s Pharm 2015.08.26

BioQuiddity and Lee’s Pharmaceutical Enter Agreement to Jointly Commercialize - Two Infusion Pharmaceuticals in China, Taiwan, Hong Kong, and Macau 2015.08.24

CVIE Therapeutics obtained approval from the Ministry of Health and Welfare for conducting Phase 2b Clinical Trial of Rostafuroxin in Taiwan 2015.08.03

Presentation at The First Chinese Symposium of Thrombosis and Haemostasis in Association with the ISTH Congress 2015.07.03

First patient enrolled in Phase Ib-IIa clinical studyof Adapalene and Clindamycin combination hydrochloride Gel for Acne Vulgaris (Moderate to severe acne) 2015.03.30

Lee’s Pharm Joins Hang Seng Broad Consumption Index, Hang Seng Mainland Consumer Goods Index, Hang Seng Global Composite Index and Hang Seng Composite Index 2015.03.09

Lee’s Zhaoke Pharmaceutical Ranks Second in 2014 for Number of Declared New Drug Application 2015.02.26

Execution of License, Distribution & Supply Agreement for Zingo® (lidocaine hydrochloride monohydrate) between Powder and Marathon 2013.11.25

First Patient Enrolled in Phase II Clinical Study of Istaroxime in Italy 2013.10.03

Lee’s Pharm announces that China registration study of Trazodone Hydrochloride Tablets for depression has met its primary endpoint 2013.10.02

Jennerex and Lee’s Pharm announces that its phase 2 study of Pexa-Vec in second-line advanced liver cancer did not meet its primary endpoint 2013.09.04

Clinical Trial Application to Conduct Phase III APEX Study of Betrixaban in China was Accepted for Review by China FDA 2013.08.28

Clinical Trial Application for Phase III study for Gimatecan was accepted for review by China FDA 2013.08.06

Powder Pharmaceuticals Hong Kong as the Manufacturing Site for ZingoTM is Approved by FDA 2013.08.01

Lee’s Present Positive Anfibatide Phase I and II Clinical Data showing “a new way to anti-platelet” at ISTH in Amsterdam 2013.07.24

Obtained Imported Drug License for Levocarnitine Oral Solution in China 2013.07.15

First Patient Enrolled in Phase III Clinical Trial of Prulifloxacin in China 2013.07.10

Powder Pharmaceuticals Hong Kong Manufacturing Facility is Acceptable by US FDA 2013.07.09

Patients Enrollment Completed in Clinical Study on Trazodone Hydrochloride Tablets for Depression 2013.06.27

First Patient Enrolled in Phase IIb Clinical Trial of Rostafuroxin in Italy 2013.06.13

Submitted Clinical Study Application to the CFDA for Istaroxime in treatment of Acute Decompensated Heart Failure in China 2013.06.03

Jennerex and Lee’s Pharmaceutical Announce Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer 2013.05.22

Lee’s Pharmaceuticals Announces it has Obtained the Imported Drug License in China forRemodulin (Treprostinil) injection 2013.04.16

Powder Pharmaceuticals Appointed Two Members to Join the Board of Directors 2013.04.09

Jennerex and Lee’s Pharmaceutical Announce Expansion of Partnership for Additional Pexa-Vec Indications in China 2013.02.26

Jennerex Announces Cancer Research Publication Demonstrating Vascular Targeting Mechanism of Action of Lead Product Candidate, Pexa-Vec (JX-594) 2013.02.13

Jennerex Announces Nature Medicine Publication Highlighting Randomized Overall Survival Benefit of Lead Product Candidate, Pexa-Vec (JX-594) in Patients with Advanced Hepatocellular Carcinoma (HCC) 2013.02.13

Dyax Corp. and CVie Therapeutics Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in China, Hong Kong and Macau 2013.02.08

Portola and Lee’s Pharmaceutical Enter into Agreement to Expand Phase 3 APEX Study of Betrixaban into China 2013.01.29

License and Supply Agreement signed to market Leuprolide in China, Hong Kong and Macau 2012.12.14

Lee’s Pharmaceutical Announces F¬¬irst Patient Treated in Phase 2b Clinical Trial of JX-594 at Queen Mary Hospital 2012.11.22

Powder Pharmaceuticals made submission to US FDA for approval of Hong Kong manufacturing facility 2012.11.02

A newspaper article reported at The Standard, “There is no cure for all our ills, but there are people who are devoted to the pursuit of making life a little bearable” 2012.10.29

Lee’s Pharmaceutical Appoints Dr. Giuseppe Bianchi to as Chief Scientific Officer 2012.10.25

Lee’s Pharmaceutical Appoint Dr. Lit-Fui Lau to its Senior Management Team 2012.10.08

Lee’s Pharm wins the Technological Achievement Award in the 2012 Hong Kong Awards for Industries 2012.08.31

Issuance of shares by CVie Therapeutics and Phase IIb Clinical Study Application for Rostafuroxin in China 2012.08.08

First patient enrolled in Phase Ib-IIa clinical study of Anfibatide for acute coronary syndrome (ACS) 2012.08.06

RegeneRx and Lee’s Pharmaceutical Complete License Agreement for Development of RegeneRx Product Candidates in China (including Hong Kong and Macau) and Taiwan 2012.07.17

Phase III clinical study of L-Carnitine on chronic Heart Failure patients with acute episode meets the primary endpoint 2012.07.11

Lee’s Pharmaceutical licenses GI safer aspirin product for China from PLx Pharma 2012.04.10

Jennerex and Lee’s Pharmaceutical Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecanin Patients with Metastatic Colorectal Cancer 2012.03.21

Obtained Medical Device Registration Certificateof Hyalofemme® from the SFDA 2012.03.14

MAJOR MILESTONE ACHIEVEMENT IN AN ASSOCIATED COMPANY 2012.02.06

Jennerex and Lee's Pharmaceutical Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer 2011.11.30

Lee’s Pharm was honored at 2011’s Forbes Asia “Best Under A Billion” Award Ceremony 2011.11.22

Jennerex and Lee's Pharmaceutical Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 2011.11.07

Submitted New Drug Application to the SFDA on Remodulin For Treatment of Pulmonary Arterial Hypertension 2011.09.12

Jennerex and Lee's Pharmaceutical Announce Publication of Interim Clinical Data of JX-594 Followed by Sorafenib Demonstrating Tumor Responses in Liver Cancer 2011.09.09

Jennerex and Lee's Pharmaceutical Announce the Publicatiion of Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic PoxvirusJX 594 to Tumors 2011.09.01

Jennerex and Lee's Pharmaceutical Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma 2011.08.03

Completed Last Patient Follow-up in Clinical Study on Acetyl L-Carnitine Tablets for treatment of Peripheral Neuropathy 2011.07.20

Jennerex and Lee's Pharmaceutical Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer 2011.05.23

Patients Enrollment completed in Clinical Study on Acetyl L-Carnitine Tablets for treatment of Peripheral Neuropathy 2011.05.12

Lee’s Pharma Announced the New Drug Registration of Natulan® for Hodgkin’s Disease in China 2011.05.09

Lee’s Pharm Announced the Completion of Phase I Study for its first-in-class drug Declotana® 2011.04.18

Patients Enrollment completed in Clinical Study on Propiverine Hydrochloride Modified Release Capsules for treatment of Urinary Incontinence 2011.04.13

Powder Pharmaceuticals Incorporated Enters into Agreement with Health-Chem Diagnostics, LLC obtaining Exclusive Manufacturing and Marketing Rights for TD Glucose in PRC, Hong Kong and other Asian Countries 2011.03.04

Propionyl-L-Carnitine Clinical Study Meets Primary and Secondary Endpoint of Treating Peripheral Arterial Diseases 2011.02.14

Approval received to initiate clinical study for Trittico® 2011.01.05
© Lee's Pharmaceutical Holdings Limited     Terms of Use   |   Privacy Statement Designed by YSD